MMS teams with Oracle for database build
MMS Holdings recently worked with Oracle Health Sciences to build a complex database for an oncology pharmaceutical company.
Archives for October 1, 2019
NEWS IN BRIEF
Glenmark opts for Horizon’s gene edited cell lines
Glenmark signs a full commercial license to utilize Horizon’s gene edited CHO cell lines to be added to the former’s biomanufacturing process.
AstraZeneca looks to N-Side for ‘a single source of truth’
AstraZeneca is implementing N-Side’s recently launched Suite for Clinical Trials to provide ‘a single source of truth’ for safely supplying trials, as more stakeholders are generating more data.
Endo ends suit against FDA over compounding case
After receiving a favorable outcome against rival compounders, Endo decides to drop its case against the FDA regarding its Vasostrict product.
CureDuchenne backs immune-resistant AAV gene therapy platform
CureDuchenne invests in Evader, a gene therapy platform created by Chameleon, which bypasses the immune responses obstructing repeated dosing.
AstraZeneca divests seven ‘mature’ brands to refocus its portfolio
AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
Rho: 'The hurdles are high when you have a drug that the world doesn’t need'
Rho experts speak to the challenges facing drug development, meeting unmet needs, quality by design, and advances in technology, among other topics, during a sit-down at the CRO’s headquarters.